Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
December 04, 2018 08:30 ET
|
Insmed, Inc.
BRIDGEWATER, N.J., Dec. 04, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...
Insmed Announces Changes to its Board of Directors
November 08, 2018 08:30 ET
|
Insmed, Inc.
—Seasoned Pharmaceutical Executive Elizabeth McKee Anderson Appointed as New Director— —Donald Hayden, Jr. Steps Down as Chairman After 13 Years of Distinguished Service— —Chief Executive Officer...
Insmed to Present at Three November Conferences
November 06, 2018 08:30 ET
|
Insmed, Inc.
BRIDGEWATER, N.J., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...
Insmed Reports Third Quarter 2018 Financial Results and Provides Business Update
October 30, 2018 07:30 ET
|
Insmed, Inc.
—Quarter Highlighted by U.S. FDA Approval of ARIKAYCE® (amikacin liposome inhalation suspension), Followed by Immediate Launch— BRIDGEWATER, N.J., Oct. 30, 2018 (GLOBE NEWSWIRE) -- Insmed...
Insmed to Host Third Quarter 2018 Financial Results Conference Call on Tuesday, October 30, 2018
October 23, 2018 08:30 ET
|
Insmed, Inc.
BRIDGEWATER, N.J., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced...
Insmed Presents New Data at IDWeek 2018 and CHEST Annual Meeting Enhancing the Understanding of MAC Lung Disease and Treatment with ARIKAYCE® (amikacin liposome inhalation suspension)
October 11, 2018 08:30 ET
|
Insmed, Inc.
BRIDGEWATER, N.J., Oct. 11, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced...
Insmed Extends Patent Protection in Japan to 2033
October 04, 2018 16:30 ET
|
Insmed, Inc.
BRIDGEWATER, N.J., Oct. 04, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced...
Insmed to Present at Two October Conferences
October 01, 2018 08:00 ET
|
Insmed, Inc.
BRIDGEWATER, N.J., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced...
Insmed Announces FDA Approval of ARIKAYCE® (amikacin liposome inhalation suspension), the First and Only Therapy Specifically Indicated for the Treatment of Mycobacterium Avium Complex (MAC) Lung Disease in Adult Patients with Limited or No Alternative Treatment Options
September 28, 2018 17:58 ET
|
Insmed, Inc.
—Commercial availability expected in early Q4 2018— —Conference call scheduled for today at 6:15 PM ET— BRIDGEWATER, N.J., Sept. 28, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a...
Pivotal Phase 3 Data from CONVERT Study of ALIS in Patients with Treatment-Refractory NTM Lung Disease Caused by MAC Published in American Journal of Respiratory and Critical Care Medicine
September 17, 2018 08:00 ET
|
Insmed, Inc.
--As previously reported, study met primary endpoint of culture conversion (p<0.0001)-- --ALIS under FDA Priority Review with PDUFA action date of September 28, 2018-- BRIDGEWATER, N.J., Sept. ...